WO2023003204A1 - Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif - Google Patents

Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif Download PDF

Info

Publication number
WO2023003204A1
WO2023003204A1 PCT/KR2022/009362 KR2022009362W WO2023003204A1 WO 2023003204 A1 WO2023003204 A1 WO 2023003204A1 KR 2022009362 W KR2022009362 W KR 2022009362W WO 2023003204 A1 WO2023003204 A1 WO 2023003204A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
obesity
present
composition
activity
Prior art date
Application number
PCT/KR2022/009362
Other languages
English (en)
Korean (ko)
Inventor
정지행
오사랑
최준희
이태후
임서준
Original Assignee
스노우화이트팩토리(주)
농업회사법인 원삼로즈힙 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스노우화이트팩토리(주), 농업회사법인 원삼로즈힙 주식회사 filed Critical 스노우화이트팩토리(주)
Publication of WO2023003204A1 publication Critical patent/WO2023003204A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Definitions

  • the present invention relates to an anti-obesity composition
  • an anti-obesity composition comprising an extract of wild genus japonica as an active ingredient.
  • Obesity is a condition in which body fat is excessively accumulated to the extent that it has a detrimental effect on health. Obesity is defined as when body fat is more than 25% of body weight in men and 30% or more in women.
  • Obesity is caused by diseases such as dysfunction of the hypothalamus and abnormal energy metabolism, as well as genetic factors, but most obesity is caused by lifestyles caused by excessive nutrient intake and reduced physical activity.
  • the consumption of instant food has increased due to the convenience of life and western eating patterns, and the lack of exercise has increased, resulting in a continuous increase in the incidence of obesity, and it is expected that this trend will intensify over time.
  • the biggest problem of obesity is not simple obesity itself, but various metabolic diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, etc. that occur as obesity continues for a long time.
  • obesity increases the risk of various diseases such as infertility, menstrual irregularity, degenerative arthritis, some cancers, sleep apnea, respiratory disorders, cholelithiasis, and depression, which is a risk factor and social problem of adult diseases.
  • Xenical a fat absorption inhibitor
  • Orlistat a component of Xenical, binds to digested fat and inhibits absorption in the intestines, thereby excreting part of the fat component as it is during meals.
  • Other drugs that have been developed include reductyl and exolyze, which promote satiety.
  • the inventors of the present inventors have made diligent research efforts to clarify the functionality in the process of conducting research on the usefulness of raw wild chimney extract. , It has an excellent effect in inhibiting the differentiation of preadipocytes, and has an effect of reducing total cholesterol and triglyceride content, so it was confirmed that there is a distinct activity in anti-obesity activity, and the present invention was completed.
  • the main object of the present invention is to provide a composition for anti-obesity containing the extract of wild genus japonica as an active ingredient.
  • Another object of the present invention is to provide a food composition containing as an active ingredient an extract of wild chives exhibiting an anti-obesity effect.
  • the present invention provides a composition for anti-obesity comprising the extract of the green fever tree as an active ingredient.
  • the present inventors conducted a study on the usefulness of the components of the extracts of the wild cypress tree, and as a result, the cypress tree extract had excellent antioxidant effects, significantly inhibited the activity of ⁇ -amylase enzyme and pancreatic lipolysis enzyme, and preadipocyte cells (preadipocyte). ), and it was confirmed that there is an excellent effect of reducing the total cholesterol and triglyceride content, and the present invention was completed.
  • the composition of the present invention is a composition for the prevention and treatment of obesity disease, which contains as an active ingredient an extract of a natural plant derived from a safe natural plant material without side effects, and is safe without side effects even when applied to the human body.
  • Rosa davurica Pall of the present invention means a deciduous shrub of the dicotyledonous plant Rosaceae Rosaceae.
  • the extract of the wild chives contains a large amount of Quercetin, Kaempferol 3,4-di-O-glucoside, Ellagic acid, and Apigenin.
  • extract refers to an extract obtained by the extraction treatment of a raw heathen tree, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a refined or purified product of the extract, or a mixture thereof, etc. , including the extract itself and extracts of all formulations that can be formed using the extract.
  • the extract of the present invention may be preferably prepared and used in the form of a dry powder after extraction.
  • the method for extracting the extract is not particularly limited, and can be extracted according to a method commonly used in the art.
  • Non-limiting examples of the extraction method include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination with two or more extraction methods.
  • the type of extraction solvent used for extracting the natural heat guava tree is not particularly limited, and any solvent known in the art may be used.
  • the extraction solvent include water; C1 to C4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof may be used, and preferably, water, lower alcohol, 1,3-butylene glycol, and ethyl acetate may be used alone or in combination of two or more.
  • the extract obtained by hot water extraction or cold brewing is filtered to remove floating solid particles by filtering out the particles using, for example, nylon or by using cryofiltration, and then used as it is or freeze-dried, hot-air-dried, It can be used after being dried using spray drying or the like.
  • fraction refers to a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
  • a method of obtaining a fraction from the extract by treating the extract obtained by extracting the extract from the extract with a predetermined solvent may be mentioned.
  • the type of solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These may be used alone or in combination of two or more.
  • alcohol is used among the fractionation solvents, C1 to C4 alcohols may be specifically used.
  • the extract of the wild cypress tree of the present invention can be extracted from any one or more parts of the whole plant, leaf, stem, root, and fruit of the cypress tree.
  • the extract of the wild plant extract can be extracted from natural, hybrid or mutant plants, and can also be extracted from plant tissue culture.
  • the raw yeolgi tree extract is characterized in that it exhibits a preventive or therapeutic activity of obesity disease by itself.
  • prevention of the present invention refers to any action that inhibits or delays the onset of obesity or obesity-related diseases by administration of the composition according to the present invention, and the term “treatment” refers to the obesity by administration of the composition according to the present invention. or any action that improves or beneficially alters the symptoms of an obesity-related disease.
  • the extract of the wild chives has an excellent antioxidant effect, increases the ⁇ -amylase enzyme and pancreatic lipolytic enzyme inhibitory activity, increases the preadipocyte differentiation inhibitory effect, and increases the total It has been confirmed that cholesterol and triglyceride content are reduced, thereby having an excellent effect on anti-obesity.
  • composition for anti-obesity containing the extract of the present invention as an active ingredient is characterized by having antioxidant activity.
  • the experimental group treated with the extract of the present invention exhibited an overall superior antioxidant effect compared to the negative control group.
  • These antioxidant effect values were analyzed to be at a similar level when compared to the positive control group, the ascorbic acid-treated group (FIGS. 3 and 4).
  • the extract of wild lentil tree extract exhibited an excellent cytoprotective effect against oxidative stress even in adipocytes (FIG. 5).
  • the anti-obesity composition of the present invention is characterized by inhibiting the activity of ⁇ -amylase enzyme and pancreatic lipolytic enzyme.
  • the ⁇ -amylase enzyme inhibitory activity increased by 66% or more at the concentration of 250 ⁇ g/ml of the extract of the present invention (Fig. 6), compared to the negative control group, in all sections of the pancreas. It was confirmed that the inhibitory activity of the lipase enzyme was increased, and in particular, it was confirmed that the extract of the present invention was increased by 47.1% at a concentration of 250 ⁇ g / ml (FIG. 7).
  • the anti-obesity composition of the present invention is characterized by having anti-obesity activity through inhibition of differentiation of preadipocytes.
  • a 36.5% improvement in the adipocyte differentiation inhibitory effect was confirmed in the group treated with 250 ⁇ g/ml of the fresh wild chive extract of the present invention (FIG. 8).
  • the anti-obesity composition of the present invention is characterized in that it has anti-obesity activity through the effect of reducing serum total cholesterol.
  • the total cholesterol reduction effect was 8.18% and 15.5%, respectively, in the groups treated with 100 and 200mg/kg of the extract of the present invention (Fig. 9).
  • the anti-obesity composition of the present invention is characterized by having anti-obesity activity through serum triglyceride concentration.
  • the neutral fat reduction effect of 42.5% and 47.5%, respectively, was confirmed in the treatment groups of 100 and 200mg/kg of the fresh wild chive tree extract of the present invention (FIG. 10).
  • the present invention provides a pharmaceutical composition for anti-obesity comprising an extract of japonica japonica as an active ingredient.
  • the pharmaceutical composition of the present invention has excellent antioxidant effect, excellent inhibitory activity of ⁇ -amylase enzyme and pancreatic lipolytic enzyme, excellent effect on preadipocyte differentiation inhibitory effect and reduction of total cholesterol and triglyceride content Since there is, it can be usefully used as an anti-obesity pharmaceutical composition for the purpose related to the treatment and prevention of obesity.
  • the pharmaceutical composition for anti-obesity containing the extract of the present invention as an active ingredient may be prepared in the form of a pharmaceutically acceptable salt.
  • a salt may be formed by adding an acid, for example, an inorganic acid (eg, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), an organic carboxylic acid (eg, acetic acid, halo such as trifluoroacetic acid) Acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and acidic sugars (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), acidic polysaccharides (e.g.
  • hyaluronic acid chondroitin sulfate
  • arginic acid organic sulfonic acids including sulfonic acid sugar esters such as chondroitin sulfate (eg methane, sulfonic acid, p-toluene sulfonic acid), etc. may be added to form salts.
  • the pharmaceutical composition of the present invention consists of materials separated from natural extracts that are not cytotoxic, and can be administered orally or parenterally during clinical administration, and can be used in the form of general pharmaceutical preparations.
  • the pharmaceutical composition of the present invention can actually be administered in various oral or parenteral formulations.
  • commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used.
  • It is prepared by Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
  • witepsol macrogol, tween 61, cacao butter, liurine fat, glycerogeratin, and the like may be used.
  • the pharmaceutical composition of the present invention may be mixed with various pharmaceutically acceptable carriers such as physiological saline or organic solvents, and may be mixed with carbohydrates such as glucose, sucrose or dextran to increase stability or absorption.
  • various pharmaceutically acceptable carriers such as physiological saline or organic solvents
  • carbohydrates such as glucose, sucrose or dextran to increase stability or absorption.
  • antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers can be used as pharmaceuticals.
  • the effective dose of the pharmaceutical composition of the present invention is 0.01 mg/kg to 10 mg/kg, preferably 0.1 mg/kg to 1 mg/kg, and may be administered once to three times a day.
  • the total effective amount of the pharmaceutical composition of the present invention can be administered to the patient in a single dose in the form of a bolus or by infusion for a relatively short period of time, and can be administered in multiple doses. This may be administered by a fractionated treatment protocol in which administration is administered over a long period of time. Since the effective dose of the patient is determined considering various factors such as the patient's age and health condition as well as the drug administration route and number of treatments, considering this point, those of ordinary skill in the art can use the present invention It will be possible to determine an appropriate effective dosage according to the particular use as a pharmaceutical composition of the.
  • the present invention provides a food composition for anti-obesity comprising the extract of the plant as an active ingredient.
  • the extract of the present invention is as described above.
  • the food composition may be used in the form of health functional food, but is not limited thereto.
  • the food composition of the present invention may be included in the form of an extract of Saengyeolgi tree, a fraction thereof, or a processed product thereof.
  • the composition may include a food additive that is acceptable in food science in addition to the active ingredient.
  • food supplement additive refers to a component that can be added to food supplementally, and can be appropriately selected and used by those skilled in the art as being added to prepare a health functional food of each formulation.
  • food additives include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.
  • the food composition of the present invention may include health functional food.
  • health functional food refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionality for the human body.
  • functionality means obtaining useful effects for health purposes, such as adjusting nutrients for the structure and function of the human body or physiological functions.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation.
  • the formulation of the health functional food may also be manufactured without limitation as long as the formulation is recognized as a health functional food.
  • the food composition of the present invention can be prepared in various types of formulations, and unlike general drugs, it has the advantage of using food as a raw material and has no side effects that may occur when taking drugs for a long time, and has excellent portability, improving obesity It can be taken as an adjuvant to enhance its effect.
  • the health functional food of the present invention can take, and it can include all foods in a conventional sense, and it can be used interchangeably with terms known in the art, such as functional foods.
  • the health functional food of the present invention may be prepared by mixing suitable other auxiliary ingredients and known additives that may be included in food according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and Vitamin complexes, etc., can be prepared by adding the compound represented by Formula 1 according to the present invention to juice, tea, jelly, juice, etc. prepared as a main component. Also included are foods used as feed for animals.
  • the present invention provides a composition for anti-obesity comprising the extract of wild genus japonica as an active ingredient.
  • the anti-obesity composition of the present invention exhibits excellent antioxidant effect, has excellent inhibitory activity of ⁇ -amylase enzyme and pancreatic lipolytic enzyme, inhibits preadipocyte differentiation, and has high total cholesterol and triglyceride content. It has an excellent effect on reduction.
  • the anti-obesity composition of the present invention is not only very safe to the human body, but also has excellent stability, as it is made from natural plant extracts, the natural plant extract, and is very safe for the human body. It can be usefully used for related anti-obesity purposes.
  • Figure 1 is a graph of the chromatogram results of the extracts of wild cypress (rosehip) for each part (A: standard mix, B: radishes, C: leaves, D: radishes, stems, E: radishes). Root, F: fresh sage fruit, peak 1: Ellagic acid, peak 2: Kaempferol 3,4-di-O-glucoside, peak 3: Quercetin).
  • Figure 2 is a graph showing the measurement of cell viability of 3T3-L1 cells, which are pre-adipocytes, according to the concentration of the extract of the present invention.
  • Figure 3 is a graph showing the measurement of DPPH radical scavenging activity according to the treatment concentration of the extract of the present invention.
  • Figure 4 is a graph showing the measurement of ABTS radical scavenging activity according to the treatment concentration of the extract of the present invention.
  • 3T3-L1 cells which are pre-adipocytes, according to the treatment concentration of the extract of the present invention.
  • Figure 6 is a graph showing the ⁇ -amylase enzyme activity inhibition rate measured according to the treatment concentration of the extract of the present invention.
  • Figure 7 is a graph showing the measurement of the pancreatic lipolytic enzyme activity inhibition rate according to the treatment concentration of the raw heat chimney extract of the present invention.
  • 3T3-L1 cells which are pre-adipocytes, according to the treatment concentration of the fresh tropical fruit extract of the present invention.
  • Figure 9 is a graph showing the measurement of the total cholesterol content according to the concentration of the treatment of the extract of the present invention in an animal model induced with a high-fat diet.
  • Figure 10 is a graph showing the measurement of the neutral fat content according to the treatment concentration of the raw pyrrhiza sinensis extract of the present invention in an animal model induced with a high-fat diet.
  • a fruit extract of the fruit of the fruit of the wild plant was prepared in the same manner as in Preparation Example 1-1, except that the fruit of the plant of the wild plant was used.
  • Example 2 Component analysis of the extract of fresh genus japonica
  • the content of the indicator component of the extracts of the wild genus japonica prepared in Example 1 was compared and analyzed.
  • High performance liquid chromatography analysis was performed using Thermo UHPLC U3000.
  • HPLC analysis conditions were as follows.
  • the column used was a Sunfire TM C18 column (Waters, 250 ⁇ 4.6 mm, 5 ⁇ m), and the column temperature was 30 ° C.
  • the UV wavelength was measured at 280 nm, and water containing 0.1% formic acid and acetonitrile (gradient mode) were used as the mobile phase.
  • the fresh rhododendron extract (Preparation Examples 1-1 to 1-5) prepared in Example 1 was dissolved in a mobile phase solvent at a concentration of 1 mg/ml, and 10 uL was injected, followed by measurement at a flow rate of 1 ml/min.
  • the content of the marker component of the extract is shown in [Table 1].
  • the outposts of the genus japonica are rich in ellagic acid, kaempferol 3,4-di-O-glucoside, and quercetin. It was analyzed as containing some Apigenin.
  • the leaves of the green fever plant contain ellagic acid, quercetin, and apigenin, and the roots of the green fever plant contain ellagic acid and quercetin. analyzed.
  • 3T3-L1 preadipocytes (ATCC CL-173, American Type Culure Collection, Manassas, USA) were cultured using DMEM containing 10% bovine calf serum, and differentiation induction and DMEM containing 10% fetal bovine serum was used as a maturation medium, and cultured in an incubator at 37°C and 5% CO 2 conditions.
  • the extract prepared in Preparation Example 1-1 was treated at concentrations of 1, 10, 50, 100, and 250 ⁇ g/ml, respectively, After 48 hours, MTT (tetrazolium bromide salt) was treated and incubated for 2 hours. After culturing, all the culture medium was removed, and formazin produced by dispensing 100 ⁇ l of DMSO was dissolved, and absorbance was measured at 570 nm (determination wave) and 690 nm (reference wave) wavelengths using a microplate reader.
  • Oxidative stress activates the signal transduction system of nerve cells, increases the generation of reactive oxygen species such as hydrogen peroxide, and reduces the expression of antioxidant enzymes.
  • the increase in reactive oxygen species changes the structure of genes and proteins, destroys intracellular and extracellular homeostasis, and causes damage to nerve cells.
  • the inhibitory activity of DPPH radical one of the reactive oxygen species that causes damage to nerve cells, is an important index for evaluating antioxidant efficacy.
  • ABTS 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) radical cation scavenging ability shows a unique blue-green color when ABTS radical is generated by the reaction of diammonium salt with potassium persulfide. It is a method to measure decolorization to light green as a sample showing antioxidant effect is added.
  • Antioxidant capacity measurement test using ABTS radical was performed by mixing 7 mM 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) and 2.4 mM potassium persulfide, blocking light for 16 hours before use, and incubating at room temperature. reacted After the reaction, 1, 10, 50, 100, and 250 ⁇ g / ml (in PBS, pH 7.4) was added and reacted, centrifuged after 10 minutes, and only the supernatant was obtained and absorbance was measured at 734 nm. For comparative experiments, ascorbic acid was used as a positive control.
  • 3T3-L1 preadipocytes (ATCC CL-173, American Type Culure Collection, Manassas, USA) were mixed with 5% FBS (fetal bovine serum), 10% horse It was inoculated into DMEM medium containing serum, 50 units/ml penicillin and 100 ⁇ g/ml streptomycin, and subcultured for 24-48 hours at 37°C, 5% CO 2 conditions, and used for experiments.
  • FBS fetal bovine serum
  • 3T3-L1 cells were dispensed at a concentration of 1.2 ⁇ 10 5 to 10 6 , and treated with the extract of the present invention (Preparation Example 1-1) at concentrations of 1, 10, 50, 100, and 250 ⁇ g/ml for 48 hours cultured for a while. After culturing, wash twice with sterilized PBS (pH7.4), add 80 ⁇ l of 0.2% NBT solution, react in a CO 2 incubator for 90 minutes, and use a 7:3 mixture of DMSO and 1N KOH. Dark blue formazen was all eluted, and absorbance was measured at 570 nm using a micro plate. For comparative experiments, commercially available orlistat (tetrahydrolipstatin component) as an anti-obesity drug was used as a positive control group.
  • orlistat tetrahydrolipstatin component
  • the fresh genus japonica extract prepared in Example 1 is a glycolytic enzyme of ⁇ -amylase.
  • the effect on activity was tested.
  • the extract of the present invention was mixed with 0.1 M sodium phosphate buffer (pH 6.9) and 0.5 unit/ml of ⁇ -amylase enzyme at concentrations of 1, 10, 50, 100, and 250 ⁇ g/ml, respectively. The solutions were mixed and incubated at 37°C for 10 minutes.
  • pancreatic lipase inhibitory activity was performed by modifying the method performed by Kim et al. Specifically, porcine pancreatic lipase was dissolved in an enzyme buffer solution (10 mM MOPS, 1 mM EDTA, pH 6.8) at a concentration of 0.5 g/200 ml while maintaining 4° C., and the lysate was centrifuged at 4,000 rpm After that, the supernatant was mixed with Tris buffer (100 mM Tris-HCl, 5 mM CaCl 2 , pH 7.0) and enzyme buffer.
  • Tris buffer 100 mM Tris-HCl, 5 mM CaCl 2 , pH 7.0
  • the inhibitory activity of the pancreatic lipase enzyme of the extract of the present invention was slightly lower than that of the positive control group. It has been reported that there are various side effects such as absorption inhibition. Therefore, it is expected that the extract of the present invention composed of natural ingredients can be effectively used as an alternative to anti-obesity drugs made of conventional compounds in that it inhibits the activity of pancreatic lipase enzyme without side effects.
  • 3T3-L1 preadipocytes (ATCC CL-173, American Type Culure Collection, Manassas, USA) were differentiated to determine the degree of fat accumulation in adipocytes. It was measured through Oil-red-O staining.
  • 3T3-L1 cells were dispensed at a number of 5 ⁇ 10 4 cells in a 24-well plate, and then maintained for 2 more days after the wells were 100% filled with cells.
  • Adipocyte differentiation was induced for 2 days in 10% FBS DMEM medium containing MDI [0.5mM 3-isobutyl-1-methylxanthine (IBMX), 1 ⁇ M dexamethasone, 1 ⁇ M insulin], and after 48 hours of culture, 2 ⁇ M insulin was added. It was cultured for two days in a medium containing 10% FBS DMEM.
  • MDI 0.5mM 3-isobutyl-1-methylxanthine (IBMX), 1 ⁇ M dexamethasone, 1 ⁇ M insulin
  • the culture medium was replaced with 10% FBS DMEM for 4 days at 2-day intervals.
  • each culture was treated with the extract of the present invention prepared in Preparation Example 1-1 at concentrations of 1, 10, 50, 100, and 250 ⁇ g/ml, and at 8 On the first day, Oil-red-O staining was performed to confirm the degree of fat accumulation.
  • the extract of the present invention composed of natural ingredients is expected to be effectively used as an alternative to anti-obesity drugs made of conventional compounds in that it effectively inhibits adipocyte differentiation without side effects.
  • mice C57BL/6 5-week-old male mice with an average weight of 20 ⁇ 1 g were used in the experiment after a 1-week adaptation period.
  • the experimental group was divided into 4 groups of 5 so that each group had a similar body weight by the egg mass method, and all groups except for the normal diet group were fed a high-fat diet containing 60% of total calories as fat for 6 weeks to induce obesity.
  • the experimental environment was maintained at a temperature of 22 ⁇ 1 ° C and humidity of 50 ⁇ 5%, a light-dark cycle was adjusted to 12 hours, and water and food were freely fed during the breeding period.
  • the breeding management of all laboratory animals was in accordance with the Laboratory Animal Use and Breeding Management Regulations, and the entire process of the experiment was conducted with the approval of the Animal Experimentation Ethics Committee of Kyung Hee University.
  • the classification and dietary composition of the experimental group are summarized in [Table 2].
  • the total lipid content of serum was measured according to the method of Frings et al., after adding phospho-vanillin reagent to serum and incubating at 37 ° C for 15 minutes, measuring absorbance at 540 nm using the sample-free group as a control group, and calculated by a standard calibration curve. .
  • Total cholesterol content was measured using a kit reagent (AM 202-k, Asan, Korea) for measuring total cholesterol
  • triglyceride content was measured using a kit reagent (AM 157S-k, Asan, Korea) for measuring triglyceride.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition anti-obésité comprenant un extrait de Rosa davurica en tant que principe actif. Une composition anti-obésité de la présente invention présente un excellent effet antioxydant, inhibe efficacement l'α-amylase et la lipase pancréatique, inhibe la différenciation des préadipocytes, et fait baisser le cholestérol et les triglycérides sanguins, et présente ainsi d'excellents effets dans le traitement et la prévention de l'obésité. De plus, une composition anti-obésité de la présente invention contient, en tant que matière première, un extrait de Rosa davurica, qui est une substance végétale naturelle, si bien qu'elle est très sûre et présente une excellente stabilité, et peut donc être utilisée efficacement contre l'obésité en rapport avec le traitement et la prévention de l'obésité dans les domaines des aliments et des produits pharmaceutiques.
PCT/KR2022/009362 2021-07-21 2022-06-29 Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif WO2023003204A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210095242A KR20230014156A (ko) 2021-07-21 2021-07-21 생열귀나무 추출물을 유효성분으로 포함하는 항비만용 조성물
KR10-2021-0095242 2021-07-21

Publications (1)

Publication Number Publication Date
WO2023003204A1 true WO2023003204A1 (fr) 2023-01-26

Family

ID=84980227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/009362 WO2023003204A1 (fr) 2021-07-21 2022-06-29 Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif

Country Status (2)

Country Link
KR (1) KR20230014156A (fr)
WO (1) WO2023003204A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102597809B1 (ko) * 2023-03-02 2023-11-07 농업회사법인 맑을청웰빙 주식회사 체지방 감소를 위한 다이어트 조성물 및 그 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010999A (ko) * 2000-07-31 2002-02-07 김석남 항산화 활성이 있는 생열귀나무 추출물 및 이를 이용한플라반계 화합물의 제조방법
KR20100111088A (ko) * 2009-04-06 2010-10-14 강원대학교산학협력단 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물
KR20180039566A (ko) * 2016-10-10 2018-04-18 경상대학교산학협력단 생열귀 추출물을 유효성분으로 함유하는 당뇨병의 예방, 개선 또는 치료용 조성물
KR101894807B1 (ko) * 2017-04-28 2018-09-04 경상대학교산학협력단 생열귀나무 추출물을 유효성분으로 함유하는 항균용 조성물
KR20200027449A (ko) * 2018-09-04 2020-03-12 한국식품연구원 생열귀나무 추출물을 이용한 호흡기 질환 개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020010999A (ko) * 2000-07-31 2002-02-07 김석남 항산화 활성이 있는 생열귀나무 추출물 및 이를 이용한플라반계 화합물의 제조방법
KR20100111088A (ko) * 2009-04-06 2010-10-14 강원대학교산학협력단 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물
KR20180039566A (ko) * 2016-10-10 2018-04-18 경상대학교산학협력단 생열귀 추출물을 유효성분으로 함유하는 당뇨병의 예방, 개선 또는 치료용 조성물
KR101894807B1 (ko) * 2017-04-28 2018-09-04 경상대학교산학협력단 생열귀나무 추출물을 유효성분으로 함유하는 항균용 조성물
KR20200027449A (ko) * 2018-09-04 2020-03-12 한국식품연구원 생열귀나무 추출물을 이용한 호흡기 질환 개선용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHEN CHUN-YAN, HAO YUN-FANG, HAO ZHAN-XI, LIU QIANG, ZHANG LU, JIANG CUI-PING, JIANG JIAN-GUO: "Flavonoids from Rosa davurica Pall. fruits prevent high-fat diet-induced obesity and liver injury via modulation of the gut microbiota in mice", FOOD & FUNCTION, R S C PUBLICATIONS, GB, vol. 12, no. 20, 19 October 2021 (2021-10-19), GB , pages 10097 - 10106, XP093026544, ISSN: 2042-6496, DOI: 10.1039/D1FO01373D *
YING WEI, MUYI CAI, RUIZENG GU, JUN LU, FENG LIN, BAOPING JI: "In vitro antioxidant activity and inhibitory hepatic steatosis effect on oleic acid-induced fatty liver model of consecutive extracts from Rosa davurica Pall", AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 12, no. 31, pages 4944 - 4951, XP093026542, DOI: 10.5897/AJB11.3997 *

Also Published As

Publication number Publication date
KR20230014156A (ko) 2023-01-30

Similar Documents

Publication Publication Date Title
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
KR101908221B1 (ko) 금방동사니 추출물을 포함하는 항비만 조성물
WO2023003204A1 (fr) Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif
KR100587398B1 (ko) 항지방화 및 항비만 활성을 갖는 박과 식물 추출물 또는이로부터 분리한 정제물을 포함하는 조성물
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2014035035A1 (fr) Composition pharmaceutique contenant un extrait complexe d'aurantii nobilis pericarpium et de crataegus en tant que principe actif, dans le traitement ou la prévention de l'obésité ou de maladies métaboliques d'origine lipidique
JP7303582B2 (ja) インディアングーズベリー抽出物と大麦若葉抽出物との複合物（ｉｂ複合物）を有効成分として含む肥満及び／または糖尿を伴うメタボリックシンドロームの予防、改善治療用組成物
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
KR102342437B1 (ko) 금화규 추출물을 유효성분으로 포함하는 항비만용 조성물
KR101303306B1 (ko) 으름덩굴 추출물을 함유하는 비만증 치료 및 예방용 조성물
KR20200012363A (ko) 어수리 지하부 및 사상자 혼합 추출물을 유효성분으로 포함하는 비만의 예방, 개선 또는 치료용 조성물
KR101084942B1 (ko) 천우슬을 이용한 관절염 치료제
KR101293835B1 (ko) 황기 및 차전초의 복합 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물.
KR101501381B1 (ko) 드라콘토멜론 마크로카펌 추출물을 포함하는 항비만 조성물
KR20140114950A (ko) 백두구 추출물을 포함하는 항비만 조성물
WO2015152653A1 (fr) Composition comprenant un extrait de feuilles de génépi blanc
KR101871318B1 (ko) 밤나무 추출물을 함유하는 항비만용 조성물
KR20210079828A (ko) 개똥쑥 추출물, 후박 추출물 또는 이들의 혼합 추출물을 포함하는 항염증, 비만 및 비알콜성 지방간 질환의 개선, 예방 또는 치료용 조성물
WO2015108332A1 (fr) Composition pour prévenir et traiter une maladie cardiovasculaire
WO2021246703A1 (fr) Composition anti-obésité
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2015167239A1 (fr) Composition contenant de l'extrait d'impératoire
KR102025572B1 (ko) 고욤나무 잎 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22846076

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE